Emily Bleimund is a member of the 2022 Expert Review Committee for the Access to Medicine Index.
Emily is Director of Trade and Health in the U.S. Department of Health and Human Services (HHS) Office of Global Affairs. In this role, she represents the United States in multilateral health forums, develops HHS positions on trade-related issues, and represents HHS in international trade negotiations and in the U.S. government interagency trade policy process. Her principal topics of focus include access to medicines, intellectual property rights, health products regulation and pricing, nutrition policy and tobacco control.
Prior to her current position, Emily worked at the FDA’s Center for Tobacco Products where she served as International Policy Counsel in the Office of Policy. In that role, Emily was the Center’s main point of contact for international issues, including the World Trade Organization dispute regarding the U.S. ban on clove cigarettes and the negotiations for the Trans-Pacific Partnership (TPP). Early in her career, Emily also worked for the American Cancer Society, where she focused on international tobacco control issues.